The skin gateway
to the Immune System


DBV Technologies is led by an experienced management team with a proven track record of developing scientific and medical products and bringing them to market. The Executive Committee assists the Chairman and CEO in the strategic and operational management of the Company. It meets once a week and is composed of the CEO, the Chief Financial Officer, Director and Technical and Director of Development.

The Executive Committee has the support of the Directors’ Committee, which is the instance of operational review of the Company's projects. The Directors’ Committee meets once a month and consists of the Executive Committee members and key managers of the Company. The Directors’ Committee endorsed the annual objectives of the Company. CODIR meets including through annual reviews and quarterly for the purpose of reviewing and analyzing the operational and financial performance of the Company, particularly in the context of Forecast Review (FR).

Pierre-Henri Benhamou
Co-founder and Chairman and Chief Executive Officer (CEO)
Physician, pediatrician, specialized in pediatric gastroenterology. Dr. Benhamou has held numerous important clinical positions, including that of Senior Consultant at the Saint-Vincent-de-Paul Hospital in Paris. At the head of DBV Technologies, of which he is currently the Chief Executive Officer, he received the prize for technological innovation from the Altran Foundation for Innovation in 2003 for his work on the development of test patches allowing the allergy to cow's milk to be diagnosed. Also holding the position of Chief Scientific Officer, PH Benhamou has published numerous works and participated in many scientific collaborations.
Bertrand Dupont
Co-founder and Chief Industrial Officer
An engineering graduate of the school of Arts et Métiers of Paris and an agrégé in mechanical engineering, before the creation of DBV Technologies, Bertrand had a career as a teacher and consultant. Beginning in 1996, he began to put his skills and expertise in mechanical engineering to use in biomedical research. Since 2000, he has been at the core of the development of the Viaskin® patches and applications. As Chief Technical Officer, Bertrand is a key figure in the development of the Viaskin® technology and the application systems. He is responsible for all the industrial processes and machines developed around the Viaskin® technology. Bertrand is a member of the Executive Committee.
David Schilansky
Chief Financial Officer
A graduate of the Université de Paris Dauphine and Imperial College in London, David supervises all the financial work as well as the partnership and Business Development activities. He previously held the position of Deputy CFO of the Ipsen group, which he had joined in 2006. David held important positions within the Administration and Finance Department, and in particular, he participated in various external growth operations and in the creation of the Investor Relations function. David also held the position of Interim Chief Financial Officer in 2011 and was a member of the Executive Committee. Before joining Ipsen, David spent three years at UBS Warburg in the field of mergers and acquisitions, and then three years at Thomson, as co-manager of investor relations. David is a member of the Executive Committee.
Charles Ruban
Chief Development Officer
Graduate of the Ecole Centrale de Lyon, a Master of Science in Biomedical Engineering from Harvard-MIT Division of Health Sciences and Technology and an Executive MBA from INSEAD, Charles oversees all development activities from manufacturing and quality control to clinical trials and Regulatory Affairs. Before joining DBV Technologies, Charles Ruban served as Senior VP, Product Development at Stallergènes, and was a member of the Executive Committee. After nine years of experience in management consulting for Europroup in Europe, Charles spent 10 years at Stallergènes. He started as Director Supply Chain and evolved as Director of R & D program, before taking the head of Product Development. Charles is a member of the Executive Committee.
Laurent Martin
Director of Regulatory Affairs
A pharmacist with a degree from the Université René Descartes in Paris and an M.B.A. from IAE Paris Sorbonne and a Master of Law in Public Health from the faculty of Sceaux, he joined DBV Technologies with more than 15 years of experience in the pharmaceutical industry. He has extensive experience in the management of international pharmaceutical development projects in Europe and the United States and in marketing authorizations, particularly in Europe with the European Medicines Agency (EMA) via the centralized procedure. He acquired his expertise in regulatory affairs through various pharmaceutical companies, such as Galderma, Guerbet, and finally, Orphan Europe, a company specialized in the development and marketing of orphan drugs, in which his last position was as Interim Managing Pharmacist, Manager of Pharmaceutical and Pre-Clinical Development, and Quality Assurance Manager. Laurent coordinates the pharmaceutical development, the regulatory filings related to the clinical studies of the products being developed, and the international registration of the medicines of DBV Technologies. Laurent is a member of the Directors’ Committee.
Wence Agbotounou
Director of Clinical Studies
With a Doctorate in Pharmacology from the Université Pierre et Marie Curie in Paris and an Executive M.B.A. from the ESCP, the European School of Management based in Paris, in the past, he held project management positions in several global, highly reputed contract research organizations (CROs), such as Quintiles and PRA International. As Head and then Director of International Clinical projects, he launched and led successfully on a global scale Phase II and III clinical trials for medium- and large-scale pharmaceutical laboratories, including several pivotal Phase III trials in immunotherapy. Wence is a member of the Directors’ Committee.
Pascale Ehouarn
Industrial Development and Production Director
Since 2006, at DBV, Pascale participates in the development of processes and machine design, and is responsible for the production of pharmaceutical patches for allergy desensitization. With a PhD in Plasma Physics from the University of Paris XI, she completed her thesis and then did a valuation study at Supélec on the electrospray process of water assisted by electrical discharges, in collaboration with EDF. Pascale also completed a post-doctorate at the University of Karlsruhe in Germany, on the packaging of nanopowders by shock, in partnership with BASF. She then secured a position as an R&D Project Manager, France Unaxis, Displays Division, in charge of particulate contamination control in production systems by plasma deposition of thin films by PECVD and PVD sites in Taiwan. Pascale is a member of the Directors’ Committee.
Lucie Mondoulet
Director of Research Department
Lucie obtained a biochemical and food engineering degree from the Institut National des Sciences Appliqués [National Institute of Applied Sciences, "INSA,” Toulouse] before specializing in the field of food allergies. Her doctorate was completed at the Institut National de la Recherche Agronomique [French National Institute for Agricultural Research, "INRA"] in the immunology and food allergies unit, in which she studied the biochemical composition of peanut allergens and the effects of heat and enzymatic treatments on the allergenicity of peanut allergens. Her specialization was continued with one year of post-doctoral work at the Centre National de la Recherche Scientifique [French National Centre for Scientific Research, "CNRS"] in Paris in the Department of Allergies and the Environment, where she was responsible for the purification of pollen allergens and the study of the repertoire of immunological responses among allergy patients. A member of the research staff of DBV Technologies as a research engineer first of all, she refined all the pre-clinical models (pharmacology) necessary for the characterization of the products of the Company before assuming responsibility for the coordination of the research staff, under the responsibility of PH Benhamou. Her research work has been the object of numerous reports in national and international conferences, publications in reviewed scientific journals, and patents. Lucie is a member of the Directors’ Committee.
Claude Thébault
Medical Director
Graduated from Paris V University, France, with an extensive background in medical science and R&D acquired during her 20+ years’ experience in Pharmaceutical Industry, Claude Thébault, joined DBV Technologies as Medical Director. Holding a master’s degree in biological & medical sciences, she started at headquarter Rhône Poulenc Rorer as an international Biostatistician Manager. She then obtained a Post-doc University diploma (DIU) on Sleep Disorders including Respiratory Diseases and was involved in many clinical studies in asthma & allergy. During the first 9 years inside Rhône-Poulenc Rorer, she held various positions, including one as international Physician Manager on Allergy products. She also worked as European Clinical Development Manager, Vaccine division, for Aventis Pasteur MSD and was a primary leadership force of R&D Department operations and projects for ALTANA Pharma’s Respiratory and Gastroenterology lines. Prior to joining, during seven years, she provided decisive leadership and direction for Medical Affairs of Roche and Besins Healthcare’s Operations. Claude is a member of the Director’ Committee.
Nathalie Donne
Director of Corporate Communication & Business Development
She holds a degree in biology at the University Paris VI France (DEA cardiovascular pharmacology) and a Masters in Biotechnology Innovation Institut National Agronomique Paris and Reims Management School. She then became Product Manager at DBV Technologies from 2003 to 2006, where she worked first Product Diallertest ® Milk then became project manager between 2006 and 2009. She is currently Director of Corporate Communication & Business Development and presents to the Directors’ Committee as Secretary of this instance.

DBV Technologies is constantly recruiting talented candidates who wish to respond to the challenges of the Biotechnological field. If you wish to join our team and contribute to the growth of DBV Technologies, please send your C.V and cover letter to this address.

Legal Mention

CNIL number: 1544201 v 0

DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
92220 Bagneux
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83

SIRET: 441772522 00013
RCS: Nanterre

Executive editor: Pierre-Henri Benhamou

Hosting service: OVH

Design : l’enchanteur


Terms of Use

Forward-Looking Statements.

This website contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. DBV assumes no obligation to update any forward-looking statements appearing on this website in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.


DBV may make improvements and/or changes to this website at any time. Although we attempt to periodically update information on this website, the information, materials and services provided on or through this website may occasionally be inaccurate, incomplete or out of date. DBV does not have a duty to update information contained in this website, and DBV will not be liable for any failure to update such information. We make no representation as to the completeness, accuracy or currency of any information on this website, and we undertake no obligation to update or revise the information contained on this website, whether as a result of new information, future events or circumstances or otherwise. It is your responsibility to verify any information contained in this website before relying upon it.


This website may contain links to websites operated by other parties. The linked sites are not under the control of DBV, and DBV is not responsible for the content available on any other Internet sites linked to this website. Such links do not imply DBV’s endorsement of material on any other site, and DBV disclaims all liability with regard to your access to such linked websites. DBV provides links to other Internet sites as a convenience to users, and access to any other Internet sites linked to this website is at your own risk.